文献速递脑血管病

卵圆孔未闭封堵术与PASCAL分类系统:净获益与净 harm 的个体化选择

Patent Foramen Ovale Closure in Stroke and the PASCAL Classification System.
PubMed 文献 · JAMA Neurol · 2026-01-01

该研究基于SCOPE联盟6项随机试验的个体参与者数据,评估PASCAL分类系统能否识别PFO封堵的净获益与净 harm。结果显示,PASCAL probable 和 possible 组封堵后5年复发性缺血性卒中绝对减少大于围术期后新发房颤增加,而 unlikely 组无卒中减少且房颤增加更明显。

要点

  • PASCAL probable 组封堵净获益:5年卒中绝对减少2.5%大于新发房颤增加1.3%。
  • PASCAL possible 组同样净获益:卒中减少3.4%大于房颤增加1.1%。
  • PASCAL unlikely 组净 harm:卒中未减少且新发房颤增加4.6%。

核心结论

  • 在年轻及中年隐源性卒中合并PFO患者中,PASCAL分类可区分约4/5 probable和possible组净获益与约1/5 unlikely组净 harm。

研究设计与样本

  • 本研究为SCOPE联盟荟萃分析的二次分析,纳入全部6项经导管PFO封堵vs单纯抗血栓治疗的随机试验个体数据,共3740例患者。
  • 患者平均(SD)年龄45(10)岁,2000至2017年在北美、欧洲、澳大利亚、巴西和韩国医院入组,本次分析于2025年1月至8月进行。

主要发现

  • 全部6项试验中PASCAL分类probable 1382例(37.0%)、possible 1811例(48.4%)、unlikely 547例(14.6%)。
  • 4项宽入组标准试验的2967例中,probable 860例(29.0%)、possible 1565例(52.7%)、unlikely 543例(18.3%)。
  • probable组5年复发性缺血性卒中绝对减少2.5%(95%CI -4.2%至-1.3%),围术期后新发房颤增加1.3%(95%CI 0.0%至2.5%)。
  • possible组卒中减少3.4%(95%CI -5.4%至-1.3%),新发房颤增加1.1%(95%CI -0.5%至2.6%)。
  • unlikely组卒中未减少(增加0.4%,95%CI -4.0%至4.8%),新发房颤增加4.6%(95%CI 0.3%至8.9%)。

临床怎么用

  • 对年轻及中年隐源性卒中合并PFO患者,可用PASCAL分类评估封堵的净获益与净 harm,probable和possible组更可能净获益。
  • PASCAL unlikely组封堵未见卒中减少且房颤增加更明显,应避免封堵。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patent foramen ovale (PFO) closure decreases recurrent stroke but increases atrial fibrillation (AF). Careful selection of patients in whom PFO is more likely to be the cause of stroke may improve outcomes by avoiding closure in patients unlikely to benefit. OBJECTIVE: To determine whether the PFO-Associated Stroke Causal Likelihood (PASCAL) classification system identifies who will experience net benefit and net harm from PFO closure. DESIGN, SETTING, AND PARTICIPANTS: This meta-analysis was a secondary analysis of individual participant-level data from the Systematic, Collaborative, PFO Closure Evaluation (SCOPE) consortium meta-analysis, including all 6 randomized trials of transcatheter PFO closure vs antithrombotic therapy alone. Participants were young and middle-aged adults (mean [SD] age, 45 [10] years) with a PFO and an otherwise cryptogenic stroke. The trials were conducted in hospitals in North America, Europe, Australia, Brazil, and South Korea from 2000 to 2017. The current analysis, involving all trial participants, was performed from January to August 2025. INTERVENTIONS: Transcatheter PFO closure plus antithrombotic therapy vs antithrombotic therapy alone. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was recurrent ischemic stroke. The primary safety end point was first-ever detection of AF beyond the periprocedural period (>45 days after randomization). RESULTS: The 6 trials enrolled 3740 patients (1889 who had PFO closure, 1851 who had medical therapy); 2058 patients (55.0%) were male, and 1682 (45.0%) were female. Among patients in all 6 trials, PASCAL classified PFO relatedness to the index stroke as probable in 1382 patients (37.0%), possible in 1811 (48.4%), and unlikely in 547 (14.6%); among the 2967 patients in the 4 trials with broad entry criteria, PASCAL classified PFO relatedness as probable in 860 patients (29.0%), possible in 1565 (52.7%), and unlikely in 543 (18.3%). The reduction in the absolute rate of recurrent ischemic strokes over 5 years was greater than the increase in first-ever detection of AF in the postperiprocedural period as follows: in the probable group, fewer strokes, -2.5% (95% CI, -4.2% to -1.3%) vs more late AF, 1.3% (95% CI, 0.0% to 2.5%), and in the possible group, fewer strokes -3.4% (95% CI, -5.4% to -1.3%) vs more late AF, 1.1% (95% CI, -0.5% to 2.6%). Reduction in recurrent ischemic strokes was not observed and increase in first-ever detected postperiprocedural AF was magnified in the unlikely group (more strokes, 0.4%; 95% CI, -4.0% to 4.8%, vs more late AF, 4.6%; 95% CI, 0.3% to 8.9%). CONCLUSION AND RELEVANCE: Among young and middle-aged patients with PFO and otherwise cryptogenic stroke, the PASCAL classification algorithm distinguished the 4 of every 5 patients in the probable and possible groups with net benefit and the 1 of every 5 patients in the unlikely group with net harm from closure.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Saver JL, Kent DM, Kasner SE, et al. Patent Foramen Ovale Closure in Stroke and the PASCAL Classification System. JAMA Neurol. 2026. PMID: 41587059. doi:10.1001/jamaneurol.2025.5446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。